• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Anti-Diabetic Drug Could Offer New Treatment for Prostate Cancer

by MM360 Staff | May 20, 2025 | Myeloma News

Source: Pharmacy Times articles Research reveals pioglitazone, a diabetes drug, may slow prostate cancer progression, offering new hope for patients with both conditions. Read More

Ruxolitinib Plus Siremadlin Yielded Superior Spleen Volume Reduction in Patients With Myelofibrosis

by MM360 Staff | May 20, 2025 | Myeloma News

Source: Pharmacy Times articles The combination demonstrated improved efficacy compared with ruxolitinib as a monotherapy. Read More

Glofit-GemOx in R/R DLBCL: FDA Advisory Committee Reviews STARGLO Phase 3 Results for Transplant-Ineligible Patients

by MM360 Staff | May 20, 2025 | Myeloma News

Source: Pharmacy Times articles Glofitamab combined with GemOx shows promising survival benefits for patients with relapsed DLBCL, offering a new treatment option for those ineligible for transplants. Read More

Mentorship, Leadership, and Professional Growth in Oncology Pharmacy

by MM360 Staff | May 20, 2025 | Myeloma News

Source: Pharmacy Times articles Don Moore, PharmD, BCPS, BCOP, DPLA, FCCP, FASHP received a leadership award at the 2025 HOPA Annual Meeting. Read More

Triple-Combination Therapy Met Primary End Point in Phase 3 Trials, Providing Treatment for Individuals With Asthma

by MM360 Staff | May 20, 2025 | Myeloma News

Source: Pharmacy Times articles A new triple-combination therapy shows promise in improving asthma management, offering hope for millions with uncontrolled symptoms. Read More

Declines in Pediatric Pneumococcal Complicated Pneumonia Evident Following Introduction of Higher Valent Vaccines

by MM360 Staff | May 20, 2025 | Myeloma News

Source: Pharmacy Times articles A systematic review reveals declining pediatric pneumococcal complicated pneumonia rates following the introduction of pneumococcal conjugate vaccine 13. Read More
« Older Entries
Next Entries »

Recent Content

  • Automated radiomics model for prediction of therapy response and minimal residual disease from baseline MRI in multiple myeloma
  • Prognostic and clinicopathological value of prognostic nutritional index in patients with multiple myeloma: a meta-analysis
  • Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses
  • Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003)
  • (no title)
  • The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: a systematic review
  • (no title)
  • Impact of residual clonal plasma cells in S-phase at the time of autologous stem cell transplantation on clinical outcomes
  • (no title)
  • Efficacy and toxicity of treatment of smoldering multiple myeloma: a systematic review and meta-analysis
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT